StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q
August 9, 2016 9:08 AM
Piper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Synergy Pharmaceuticals (SGYP) Rumor Mill Cranks Up Following Allergan CEO Comments
August 8, 2016 9:59 AM
Allergan (AGN) CEO Says Not Focused on or Looking at Large Deals (BIIB)
August 8, 2016 9:21 AM
Allergan (AGN) Tops Q2 EPS by 1c
August 8, 2016 7:02 AM
Allergan Reports Strong Second Quarter 2016 Continuing Operations Performance with Net Revenues of $3.7 Billion
August 8, 2016 7:00 AM
Allergan (AGN) August weekly volatility flat into Q2 and outlook
August 8, 2016 6:18 AM
Trading Radar for 8/8: Nuance (NUAN), LendingClub (LC), Tyson Foods (TSN), Twilio (TWLO), Hertz (HTZ) Report
August 5, 2016 2:53 PM
Allergan (AGN) August weekly volatility flat into Q2 and outlook
August 5, 2016 2:15 PM
Allergan (AGN), Richter Update on Cariprazine; MD-72 Adjunctive MDD Trial Data Said Not Significant
August 5, 2016 6:50 AM
Allergan and Richter Provide Update on Cariprazine Program
August 5, 2016 2:00 AM
